Comparative Pharmacology
Head-to-head clinical analysis: BIVALIRUDIN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIVALIRUDIN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE.
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bivalirudin is a direct thrombin inhibitor that binds specifically and reversibly to both free and clot-bound thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin, platelet activation, and clot formation.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous bolus of 0.75 mg/kg followed by continuous infusion at 1.75 mg/kg/hour for the duration of percutaneous coronary intervention (PCI). For heparin-induced thrombocytopenia (HIT) patients undergoing PCI, the same dosing is used. For HIT patients without PCI, alternative dosing may be considered.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateThe terminal elimination half-life in patients with normal renal function is approximately 25-35 minutes (mean 25 minutes). In patients with moderate-to-severe renal impairment (CrCl <30 mL/min), half-life can be prolonged to 1-3 hours. Clinical context: short half-life allows for rapid reversal upon discontinuation; however, dose adjustment is required in renal impairment.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal excretion of unchanged drug accounts for approximately 20-25% of the administered dose; the remainder undergoes hepatic metabolism and proteolysis, with subsequent renal and biliary elimination of metabolites. Fecal excretion is minimal (<5%).
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."